| 0.7101 0 (0%) | 10-15 10:46 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 0.91  |
1-year : | 1.05 |
| Resists | First : | 0.78 |
Second : | 0.89 |
| Pivot price | 0.75  |
|||
| Supports | First : | 0.6 |
Second : | 0.49 |
| MAs | MA(5) : | 0.71 |
MA(20) : | 0.76 |
| MA(100) : | 0.49 |
MA(250) : | 0.95 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 12.7 | D(3) : | 12.7 |
| RSI | RSI(14): 47.1 | |||
| 52-week | High : | 2.7 | Low : | 0.16 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ ATXI ] has closed above bottom band by 29.9%. Bollinger Bands are 5.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.71 - 0.71 | 0.71 - 0.72 |
| Low: | 0.7 - 0.71 | 0.71 - 0.71 |
| Close: | 0.7 - 0.71 | 0.71 - 0.72 |
Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, a synthetic dual-acting opioid, which is in Phase III clinical trials for the treatment of post-operative acute pain. The company was incorporated in 2015 and is based in New York, New York.
Mon, 31 Mar 2025
Avenue Therapeutics Inc. (ATXI) reports earnings - qz.com
Tue, 18 Mar 2025
Dow Dips Over 200 Points; US Industrial Production Increases More than Expected - Benzinga
Fri, 07 Mar 2025
Avenue Therapeutics granted Nasdaq extension, faces AnnJi dispute - Investing.com
Fri, 29 Nov 2024
Avenue Therapeutics faces Nasdaq delisting over equity shortfall - Investing.com
Thu, 14 Nov 2024
Avenue Therapeutics Inc (ATXI) Quarterly 10-Q Report - qz.com
Thu, 14 Nov 2024
Avenue Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 3 (M) |
| Shares Float | 3 (M) |
| Held by Insiders | 18.4 (%) |
| Held by Institutions | 3.1 (%) |
| Shares Short | 60 (K) |
| Shares Short P.Month | 155 (K) |
| EPS | 2.57 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.26 |
| Profit Margin | 0 % |
| Operating Margin | 21.1 % |
| Return on Assets (ttm) | -86.9 % |
| Return on Equity (ttm) | -185.5 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0.44 |
| Sales Per Share | 0.44 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -5 (M) |
| Levered Free Cash Flow | -3 (M) |
| PE Ratio | 0.27 |
| PEG Ratio | 0 |
| Price to Book value | 0.55 |
| Price to Sales | 1.61 |
| Price to Cash Flow | -0.46 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|